Neurogenic researches and develops diagnostics and therapeutics for mental disorders. The company has developed a straightforward, highly sensitive, and specific blood test for the diagnosis of schizophrenia in children with behavioral disorders.

Laboratory research at Neurogenic has been divided into three separate categories. The first is identifying the antigen that binds circulating schizophrenia-related auto-antibodies. The second is identifying the specific antigen peptide fragment, or epitope, that binds to the antibodies. The third is establishing an ELISA assay with epitope peptide derivatives yielding high sensitivity and specificity to the exact antibodies present in the blood of schizophrenic patients, as opposed to that of control group subjects.

The test is primarily applicable to predisposed young subjects with behavioral problems, but can categorize other mental disorders as well.

Neurogenic is a portfolio company of Wolfoson Clore Mayer (WCM) Group.